Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 5/20 | 0.61 |
| ▸ | AGL | P35573 | 2/20 | 0.60 |
| ▸ | GAA | P10253 | 5/20 | 0.53 |
| ▸ | MGAM | O43451 | 3/20 | 0.53 |
| ▸ | SI | P14410 | 2/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | LCT | P09848 | 1/20 | 0.53 |
| ▸ | GBA2 | Q9HCG7 | 5/20 | 0.47 |
| ▸ | UGCG | Q16739 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6135638 | 1.00 | GBA1 (0.61) | GBA1AGLGAAMGAMSI | |
| SCHEMBL6135460 | 1.00 | GBA1 (0.61) | GBA1AGLGAAMGAMSI | |
| Hydrochloric Acid SCHEMBL7617701 | 0.98 | GBA1 (0.59) | GBA1AGLGAAMGAMSI | |
| SCHEMBL17189572 | 0.94 | GAA (0.61) | GBA1AGLGAAMGAMSI | |
| SCHEMBL12157731 | 0.94 | GAA (0.61) | GBA1AGLGAAMGAMSI | |
| SCHEMBL2268123 | 0.91 | GBA1 (0.70) | GBA1AGLGAAMGAMSI | |
| SCHEMBL2433807 | 0.91 | GBA1 (0.70) | GBA1AGLGAAMGAMSI | |
| SCHEMBL23996647 | 0.89 | GAA (0.56) | GBA1AGLGAAMGAMSI | |
| SCHEMBL25221618 | 0.89 | GAA (0.56) | GBA1AGLGAAMGAMSI | |
| SCHEMBL23996662 | 0.89 | GAA (0.56) | GBA1AGLGAAMGAMSI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6960610-B2 | Use of glycogen phosphorylase inhibitors for treatment of cardiovascular diseases | NOVO NORDICK, A/S (DK) | 2005-11-01 | — | — | US | claimed |
| EP-1558245-A2 | USE OF GLYCOGEN PHOSPHORYLASE INHIBITORS FOR TREATMENT OF CARDIOVASCULAR DISEASES | NOVO NORDISK A/S (DK) | 2005-08-03 | — | — | EP | claimed |
| WO-2004037233-A2 | USE OF GLYCOGEN PHOSPHORYLASE INHIBITORS FOR TREATMENT OF CARDIOVASCULAR DISEASES | NOVO NORDISK A/S (DK) | 2004-05-06 | — | — | WO | claimed |
| US-20040082641-A1 | Use of glycogen phosphorylase inhibitors for treatment of cardiovascular diseases | NOVO NORDISK A/S (DK) | 2004-04-29 | — | — | US | claimed |
| US-20040082646-A1 | Use of glycogen phosphorylase inhibitors for treatment of cardiovascular diseases | RYTVED KLAUS ASGER (DK) | 2004-04-29 | — | — | US | claimed |
| EP-0858335-B1 | 2-ALKYLPYRROLIDINES | NOVO NORDISK AS (DK) | 2003-03-12 | — | — | EP | claimed |
| EP-1150674-A1 | USE OF PYRROLIDINE DERIVATIVES FOR THE MANUFACTURE OF A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OR PROPHYLAXIS OF OBESITY OR APPETITE REGULATION | NOVO NORDISK A/S (DK) | 2001-11-07 | — | — | EP | claimed |
| EP-1040827-A2 | Use of 2-alkylpyrrolidines for the treatment of diabetes | NOVO NORDISK A/S (DK) | 2000-10-04 | — | — | EP | claimed |
| WO-2000047206-A1 | USE OF PYRROLIDINE DERIVATIVES FOR THE MANUFACTURE OF A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OR PROPHYLAXIS OF OBESITY OR APPETITE REGULATION | NOVO NORDISK A/S (DK) | 2000-08-17 | — | — | WO | claimed |
| US-5854272-A | 2-alkylpyrrolidines | NOVO NORDISK A/S (DK) | 1998-12-29 | — | — | US | claimed |
| US-6960610-B2 | Use of glycogen phosphorylase inhibitors for treatment of cardiovascular diseases | NOVO NORDICK, A/S (DK) | 2005-11-01 | — | — | US | disclosed |
| EP-1558245-A2 | USE OF GLYCOGEN PHOSPHORYLASE INHIBITORS FOR TREATMENT OF CARDIOVASCULAR DISEASES | NOVO NORDISK A/S (DK) | 2005-08-03 | — | — | EP | disclosed |
| US-20050054618-A1 | Use of glycogen phosphorylase inhibitors for treatment of cardiovascular diseases | RYTVED KLAUS ASGER (DK) | 2005-03-10 | — | — | US | disclosed |
| WO-2004037233-A2 | USE OF GLYCOGEN PHOSPHORYLASE INHIBITORS FOR TREATMENT OF CARDIOVASCULAR DISEASES | NOVO NORDISK A/S (DK) | 2004-05-06 | — | — | WO | disclosed |
| US-20040082646-A1 | Use of glycogen phosphorylase inhibitors for treatment of cardiovascular diseases | RYTVED KLAUS ASGER (DK) | 2004-04-29 | — | — | US | disclosed |
| WO-2000047206-A1 | USE OF PYRROLIDINE DERIVATIVES FOR THE MANUFACTURE OF A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OR PROPHYLAXIS OF OBESITY OR APPETITE REGULATION | NOVO NORDISK A/S (DK) | 2000-08-17 | — | — | WO | disclosed |
| US-5854272-A | 2-alkylpyrrolidines | NOVO NORDISK A/S (DK) | 1998-12-29 | — | — | US | disclosed |
| EP-0884050-A1 | Use of 3,4-dihydroxy-2-hydroxymethylpyrrolidine for the treatment of diabetes | NOVO NORDISK A/S (DK) | 1998-12-16 | — | — | EP | disclosed |
| EP-0858335-A1 | 2-ALKYLPYRROLIDINES | NOVO NORDISK A/S (DK) | 1998-08-19 | — | — | EP | disclosed |
| WO-1997009040-A1 | 2-ALKYLPYRROLIDINES | NOVO NORDISK A/S (DK) | 1997-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054618-A1 | Use of glycogen phosphorylase inhibitors for treatment of cardiovascular diseases | PYGM, GYS1, AGL | GBA1 308/4885AGL 3/4885GAA 43/4885 |
| US-20040082641-A1 | Use of glycogen phosphorylase inhibitors for treatment of cardiovascular diseases | PYGM, GYS1, AGL | GBA1 308/4885AGL 3/4885GAA 43/4885 |
| US-20040082646-A1 | Use of glycogen phosphorylase inhibitors for treatment of cardiovascular diseases | PYGM, GYS1, AGL | GBA1 288/4885AGL 3/4885GAA 45/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.